A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Clinical trial NCT05134194 · TERMINATED

Trial details

NCT number: NCT05134194
Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2022-01-17
Primary completion: 2022-01-17
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.